321601-48-3

Usage

Uses

Used in Pharmaceutical Synthesis:
Methyl 6-bromo-3-hydroxypicolinate is used as an intermediate in the pharmaceutical industry for the synthesis of various drugs. Its unique structure allows for the development of new compounds with potential therapeutic effects.
Used in Agrochemical Synthesis:
In the agrochemical industry, Methyl 6-bromo-3-hydroxypicolinate serves as an intermediate for the production of pesticides and other agrochemicals, contributing to the development of effective solutions for crop protection.
Used in Organic Chemistry:
Methyl 6-bromo-3-hydroxypicolinate is used as a building block in organic chemistry for the synthesis of heterocyclic compounds. Its presence in various organic reactions facilitates the creation of complex molecular structures with potential applications in various fields.
Used in Biological Research:
Methyl 6-bromo-3-hydroxypicolinate is utilized in biological research for studying its antiparasitic and anticancer properties. Its potential to target specific biological pathways makes it a valuable compound for developing new treatments and therapies.
Used in Drug Delivery Systems:
Although not explicitly mentioned in the provided materials, given its potential biological activities, Methyl 6-bromo-3-hydroxypicolinate could be employed in drug delivery systems to improve the efficacy and targeted delivery of therapeutic agents, particularly in cancer treatment.

Upstream product

• 67-56-1 methanol 
• 874-24-8 3-hydroxypyridine-2-carboxylic acid 
• 62733-99-7 methyl 3-hydroxypicolinate 

Downstream Products

• 1585949-24-1 methyl 3-(benzyloxy)-6-(5-hydroxypent-1-ynyl)picolinate 
• 1585949-26-3 methyl 3-(benzyloxy)-6-(4-(3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)but-1-ynyl)picolinate 
• 1585949-28-5 methyl 3-(benzyloxy)-6-(5-(3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)pent-1-ynyl)picolinate 
• 1585949-22-9 methyl 3-(benzyloxy)-6-(4-hydroxybut-1-ynyl)picolinate 
• 1214330-74-1 3-methoxy-6-(trifluoromethyl)picolinic acid 
• 945954-94-9 methyl 6-bromo-3-methoxypyridine-2-carboxylate 

Relevant academic research and scientific papers

Structure-guided design of antibacterials that allosterically inhibit DNA gyrase

A series of DNA gyrase inhibitors were designed based on the X-ray structure of a parent thiophene scaffold with the objective to improve biochemical and whole-cell antibacterial activity, while reducing cardiac ion channel activity. The binding mode and overall design hypothesis of one series was confirmed with a co-crystal structure with DNA gyrase. Although some analogs retained both biochemical activity and whole-cell antibacterial activity, we were unable to significantly improve the activity of the series and analogs retained activity against the cardiac ion channels, therefore we stopped optimization efforts.

CARBALDEHYDE OXIMES AS BUTYRYLCHOLINESTERASE REACTIVATORS

The present invention relates to compounds for their use in the reactivation of butyrylcholinesterase. Such compounds are useful in the treatment or prevention of the intoxication with at least one organophosphorus nerve agent. The invention also relates

Optimization of Benzothiazole and Thiazole Hydrazones as Inhibitors of Schistosome BCL-2

Limited therapeutic options are available for the treatment of human schistosomiasis caused by the parasitic Schistosoma flatworm. The B cell lymphoma-2 (BCL-2)-regulated apoptotic cell death pathway in schistosomes was recently characterized and shown to share similarities with the intrinsic apoptosis pathway in humans. Here, we exploit structural differences in the human and schistosome BCL-2 (sBCL-2) pro-survival proteins toward a novel treatment strategy for schistosomiasis. The benzothiazole hydrazone scaffold previously employed to target human BCL-XL was repurposed as a starting point to target sBCL-2. We utilized X-ray structural data to inform optimization and then applied a scaffold-hop strategy to identify the 5-carboxamide thiazole hydrazone scaffold (43) with potent sBCL-2 activity (IC50 30 nM). Human BCL-XL potency (IC50 13 nM) was inadvertently preserved during the optimization process. The lead analogues from this study exhibit on-target activity in model fibroblast cell lines dependent on either sBCL-2 or human BCL-XL for survival. Further optimization of the thiazole hydrazone class is required to exhibit activity in schistosomes and enhance the potential of this strategy for treating schistosomiasis.

HPK1 ANTAGONISTS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

SULFONYL-SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR

Provided is a sulfonyl-substituted bicyclic compound (A) which acts as a RORγ inhibitor, said compound has good RORγ inhibitory activity and is expected to be used for treating diseases mediated by a RORγ receptor in mammals.

ROR-GAMMA INHIBITORS

The present invention relates to compounds of formula I and pharmaceutical compositions comprising compounds of formula I. Compounds of Formula I are useful in treatment of inflammatory, metabolic or autoimmune diseases which are mediated by RORy.

Combination delivery of two oxime-loaded lipid nanoparticles: Time-dependent additive action for prolonged rat brain protection

A novel approach for brain protection against poisoning by organophosphorus agents is developed based on the combination treatment of dual delivery of two oximes. Pralidoxime chloride (2-PAM) and a novel reactivator, 6-(5-(6,7-dimethoxy-3,4-dihydroisoquin

HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The invention relates to a novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an effective ingredient. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.

Tryptoline-3-hydroxypyridinaldoxime conjugates as efficient reactivators of phosphylated human acetyl and butyrylcholinesterases

Two promising uncharged reactivators for inhibited human BChE and AChE have been described. These compounds show an ability to reactivate VX-inhibited BChE largely superior to those of known pyridinium aldoximes. Moreover, these oximes also exhibit a good

TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C

The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.